A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis

Summary

This is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple AscendingDose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-488 in Healthy Subjects and Patients With Psoriasis

Timeline

Start

2022-07-29

Primary completion

2023-10-30

Completion

2023-12-31

Drugs

Indications